Role of cGMP-dependent protein kinase in development of tolerance to nitroglycerine in porcine coronary arteries

British Journal of Pharmacology

Volumn 153, Issue 3, 2008, Pages 497-507

  Dou, D ^a   Zheng, X ^a   Qin, X ^a   Qi, H ^a   Liu, L ^a   Raj, J U ^b   Gao, Y ^a,b,c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PEKING UNIVERSITY   (China)

Author keywords

8 Br cGMP; Nitric oxide; Rp 8 Br PET cGMPS

Indexed keywords

2,2' (HYDROXYNITROSOHYDRAZONO) BIS(ETHANAMINE); 8 BROMO GUANOSINE 3'5' CYCLIC MONOPHOSPHATE; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DERIVATIVE; ETHYLAMINE; GLYCERYL TRINITRATE; MESSENGER RNA; PHOSPHORUS 32; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CORONARY ARTERY; CROSS TOLERANCE; DOWN REGULATION; ENZYME ACTIVITY; INCUBATION TIME; ISOLATED ARTERY; MUSCLE RELAXATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CORONARY VESSELS; CYCLIC GMP; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; NITROGLYCERIN; POLYMERASE CHAIN REACTION; PROTEIN KINASES; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SUPEROXIDES; SWINE; VASODILATOR AGENTS;

EID: 38849198004     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707600     Document Type: Article

References (46)

1. Abou-Mohamed G, Kaesemeyer WH, Caldwell RB, Caldwell RW (2000). Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br J Pharmacol 130: 211-218.
2. Anderson PG, Boerth NJ, Liu M, McNama DB, Cornwell TL, Lincoln TM (2000). Cyclic CMP-dependent protein kinase expression in coronary arterial smooth muscle in response to balloon catheter injury. Arterioscler Thromb Vasc Biol 20: 2192-2197.
3. Atlante A, Valenti D, Gagliardi S, Passarella S (2000). A sensitive method to assay the xanthine oxidase activity in primary cultures of cerebellar granule cells. Brain Res Brain Res Protoc 6: 1-5.
4. Browner NC, Sellak H, Lincoln TM (2004). Downregulation of cGMP-dependent protein kinase expression by inflammatory cytokines in vascular smooth muscle cells. Am J Physiol Cell Physiol 287: C88-C96.
5. Butt E, Pohler D, Genieser HG, Huggins JP, Bucher B (1995). Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS. Br J Pharmacol 116: 3110-3116.
6. Chen Z, Foster MW, Zhang J, Mao L, Rockman HA, Kawamoto T et al. (2005). An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci USA 102: 12159-12164.
7. Chen Z, Stamler JS (2006). Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med 16: 259-265.
8. Csont T, Ferdinandy P (2005). Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol Ther 105: 57-68.
9. Difabio J, Ji Y, Vasiliou V, Thatcher GR, Bennett BM (2003). Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol Pharmacol 64: 1109-1116.
10. Francis SH, Corbin JD (1994). Structure and function of cyclic nucleotide-dependent protein kinases. Annu Rev Physiol 56: 237-272.
11. Gao Y, Dhanakoti S, Trevino EM, Sander FC, Portugal AM, Raj JU (2003). Effect of oxygen on cyclic GMP-dependent protein kinase-mediated relaxation in ovine fetal pulmonary arteries and veins. Am J Physiol 285: L611-L618.
12. Gao Y, Dhanakoti S, Trevino EM, Wang X, Sander FC, Portugal AD et al. (2004). Role of cGMP-dependent protein kinase in development of tolerance to nitric oxide in pulmonary veins of newborns lambs. Am J Physiol Lung Cell Physiol 286: L786-L792.
13. Gerlach H, Pappert D, Lewandowski K, Rossaint R, Falke KJ (1993). Long-term inhalation with evaluated low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome. Intensive Care Med 19: 443-449.
14. Gold ME, Bush PA, Ignarro LJ (1989). Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun 164: 714-721.
15. Hashimoto S, Kobayashi A (2003). Clinical pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its metabolites. Clin Pharmacokinet 42: 205-221.
16. Hofmann F, Ammendola A, Schlossmann J (2000). Rising behind NO: cGMP-dependent protein kinases. J Cell Sci 113: 1671-1676.
17. Hofmann F, Feil R, Kleppisch T, Schlossmann J (2006). Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 86: 1-23.
18. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ et al. (1981). Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 218: 739-749.
19. Kim D, Rybalkin SD, Pi XC, Wang Y, Zhang C, Münzel T et al. (2001). Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104: 2338-2343.
20. Kollau A, Hofer A, Russwurm M, Koesling D, Keung WM, Schmidt K et al. (2005). Contribution of aldehyde dehydrogenase to mitochondrial bioactivation of nitroglycerin: evidence for activation of purified soluble guanylate cyclase through direct formation of nitric oxide. Biochem J 385: 769-777.
21. Lincoln TM, Dey N, Sellak H (2001). cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 91: 1421-1430.
22. MacPherson JD, Gillespie TD, Dunkerley HA, Maurice DH, Bennett BM (2006). Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation. J Pharmacol Exp The 317: 188-195.
23. Meyer RBJ, Miller JP (1974). Analogs of cyclic AMP and cyclic GMP: general methods of synthesis and the relationship of structure to enzymic activity. Life Sci 14: 1019-1040.
24. Molina CR, Andersen JW, Rapoport RM, Waldman S, Murad F (1987). Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol 10: 371-378.
25. Mooradian DL, Hutsell TC, Keefer LK (1995). Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol 25: 674-678.
26. Müller A, Cadenas E, Graf P, Sies H (1984). A novel biologically active seleno-organic compound - I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (ebselen). Biochem Pharmacol 33: 3235-3239.
27. Mülsch A, Oelze M, Klöss S, Mollnau H, Töpfer A, Smolenski A et al. (2001). Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in Aorta. Circulation 103: 2188-2194.
28. Münzel T, Daiber A, Mülsch A (2005). Explaining the phenomenon of nitrate tolerance. Circ Res 97: 618-628.
29. Münzel T, Li H, Mollnau H, Hink U, Matheis E, Hartmann M et al. (2000). Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 86: E7-E12.
30. Münzel T, Sayegh H, Freeman BA, Tarey MM, Harrison DG (1995). Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying nitrate tolerance and cross tolerance. J Clin Invest 95: 187-194.
31. Nowicki PT, Flavahan S, Hassanain H, Mitra S, Holland S, Goldschmidt-Clermont PJ et al. (2001). Redox signaling of the arteriolar myogenic response. Circ Res 89: 114-116.
32. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N et al. (1998). Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 102: 2061-2071.
33. Pagani ED, VanAller GS, O'Connor B, Silver PJ (1993). Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast. Eur J Pharmacol 243: 141-147.
34. Park SJ, Lee YC (2006). Antioxidants as novel agents for asthma. Mini Rev Med Chem 6: 235-240.
35. Parker JD (2004). Nitrate tolerance, oxidative stress, and mitochondrial function: another worrisome chapter on the effects of organic nitrates. J Clin Invest 113: 352-354.
36. Qin X, Zheng X, Qi H, Dou D, Raj JU, Gao Y (2007). cGMP-dependent protein kinase in regulation of basal tone and in nitroglycerin- and nitric-oxide-induced relaxation in porcine coronary artery. Pflügers Arch-Eur J Physiol 454: 913-923.
37. Romanin C, Kukovetz WR (1989). Tolerance to nitroglycerin is caused by reduced guanylate cyclase activation. J Mol Cell Cardiol 21: 41-48.
38. Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M et al. (2002). Functional and biochemical analysis of endothelial (dys)-function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 105: 1170-1175.
39. Sellak H, Yang X, Cao X, Cornwell T, Soff GA, Lincoln T (2002). Sp1 transcription factor as a molecular target for nitric oxide- and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Ialpha expression in vascular smooth muscle cells. Circ Res 90: 405-412.
40. Soff GA, Cornwell TL, Cundiff DL, Gately S, Lincoln TM (1997). Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. J Clin Invest 100: 2580-2587.
41. Stewart DD (1888). Remarkable tolerance to nitroglycerine. Polyclinic 6: 43.
42. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wednt M et al. (2004). Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 113: 482-489.
43. van Deel ED, Merkus D, van Haperen RJ, de Waard MC, de Crom R, Duncker DJ (2007). Vasomotor control in mice overexpressing human endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 293: 1144-1153.
44. B receptor-mediated contraction of rat pulmonary arteries. Am J Physiol 290: L570-L578.
45. Yamashita T, Kawashima S, Ohashi Y, Ozaki M, Rikitake Y, Inoue N et al. (2000). Mechanisms of reduced nitric oxide/cGMP-mediated vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. Hypertension 36: 97-102.
46. Zhao R, Holmgren A (2002). A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase. J Biol Chem 277: 39456-39462.